Innovative Combo Therapy Targeting Pancreatic and Colon Cancer
The current invention is based on combination therapies of nucleoside analogs with inhibitors of either the Nodal/Activin pathway or the mTOR / hedgehog pathway and show a remarkable capacity to eliminate cancer stem cells
and to subsequently inhibit pancreatic and/or colon cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
